欢迎访问ProbeChem中文网站，英文网站请访问www.probechem.com
    英文 |     中文

产品咨询: sales@probechem.com
订购: order@probechem.com

首页-小分子抑制剂&激动剂-Cell Cycle/DNA Damage-Cyclin-dependent Kinase (CDK)-CTX-439
CTX-439

Chemical Structure : CTX-439

CAS No.: 2377487-13-1

加入收藏

CTX-439 (CTX439)

货号: PC-26376Not For Human Use, Lab Use Only.

CTX-439 is a potent, selective, orally bioavailable, ATP-competitive CDK12/13 inhibitor with IC50 of 3.1/ 9.2 nM towards CDK12/Cyclin K and CDK13/Cyclin K, respectively, in cell-free assays.

规格 价格 库存 数量
50 mg Get quote
100 mg Get quote
250 mg Get quote
获取报价单
* 请选择数量再加入购物车
 or Bulk Inquiry

大包装，大折扣！

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

纯度 & COA & 质检文件 纯度: >98% (HPLC) Select Batch:

    生物&药学活性

    CTX-439 is a potent, selective, orally bioavailable, ATP-competitive CDK12/13 inhibitor with IC50 of 3.1/ 9.2 nM towards CDK12/Cyclin K and CDK13/Cyclin K, respectively, in cell-free assays.
    CTX-439 possesses a highly specific inhibitory activity towards CDK12/13 compared to other members of the CDK family proteins, showing > 550-fold higher binding affinity and 20-fold higher inhibitory activity than the closest family member, CDK9.
    CTX-439 shows high binding affinity towards CDK12 (Kd=0.38 nM).
    CTX-439 downregulated p-S2, but neither phosphorylation of S5 (p-S5) nor phosphorylation of S7 (p-S7) in breast cancer cell line SUM149PT, reduced Serine 423 (S423) of CDK12 phosphorylation level in a dose-dependent manner.
    CTX-439 possesses profound anti-tumor effects with IC50 of 100.5 nM against SUM149PT in cell-based assay, shows anti-tumor activity against a broad range of breast and ovarian cancer cell lines.
    CTX-439 (15-30 mg/kg, p.o.) showed marked in vivo anti-tumor activity in nude mice bearing SUM149PT xenografts.

    物理化学性质&存储条件

    分子量 671.70
    分子式 C30H32F3N9O4S
    外观性状 Solid
    CAS No.
    储存条件
    固体粉末
    -20°C 12 个月; 4°C 6 个月
    配置液
    -80°C 6 个月; -20°C 6 个月
    Shipping
    Solubility

    10 mM in DMSO
    Chemical Name/SMILES

    Butanamide, N-[5-(2-methoxy-5-pyrimidinyl)-2-pyrazinyl]-N-[trans-4-[[4-[5-(methylsulfonyl)-3-pyridinyl]-5-(trifluoromethyl)-2-pyrimidinyl]amino]cyclohexyl]-

    参考文献

    1. Kenichiro Shimokawa, et al. ACS Medicinal Chemistry Letters, June 23, 2026.

    2. Kawahara S, et al. Mol Cancer Ther. 2026 Mar 12. doi: 10.1158/1535-7163.MCT-25-0954.

    备案号：沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

    联系我们 sales@probechem.com

    Bulk Inquiry

    * Indicates a Required FieldYour information is safe with us.

    • *Product name:
    • *Applicant name:
    • *Email address:
    • *Organization name:
    • *Requested quantity:
    • *Country:
    • *Additional Information:

    询单

    • *产品名称:
    • *姓名:
    • *邮箱:
    • *公司名称:
    • *询单数量:
    • *国籍:
    • 询单信息: